Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRX NASDAQ:CRVS NASDAQ:MRKR OTCMKTS:PFSCF NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsCRVSCorvus Pharmaceuticals$5.88+0.9%$4.94$2.54▼$10.00$434.42M0.51560,527 shs639,488 shsMRKRMarker Therapeutics$0.95-0.9%$1.27$0.81▼$5.95$12.35M1.522.70 million shs185,609 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AXERSXeris Biopharma$7.36-1.7%$6.54$2.69▼$8.03$1.21B0.131.83 million shs1.49 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals+0.86%-0.34%+8.29%+49.24%+15.29%MRKRMarker Therapeutics-0.91%+8.19%-24.93%-36.94%-65.91%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma-1.74%-5.28%-4.17%+62.11%+155.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRXAcelRx Pharmaceuticals$0.77$0.43▼$2.78$14.58M0.52137,683 shs243,500 shsCRVSCorvus Pharmaceuticals$5.88+0.9%$4.94$2.54▼$10.00$434.42M0.51560,527 shs639,488 shsMRKRMarker Therapeutics$0.95-0.9%$1.27$0.81▼$5.95$12.35M1.522.70 million shs185,609 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/AXERSXeris Biopharma$7.36-1.7%$6.54$2.69▼$8.03$1.21B0.131.83 million shs1.49 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRXAcelRx Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CRVSCorvus Pharmaceuticals+0.86%-0.34%+8.29%+49.24%+15.29%MRKRMarker Therapeutics-0.91%+8.19%-24.93%-36.94%-65.91%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%XERSXeris Biopharma-1.74%-5.28%-4.17%+62.11%+155.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRXAcelRx Pharmaceuticals 0.00N/AN/AN/ACRVSCorvus Pharmaceuticals 3.00Buy$13.00121.09% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.171,291.97% UpsidePFSCFProMetic Life Sciences 0.00N/AN/AN/AXERSXeris Biopharma 2.83Moderate Buy$7.08-3.76% DownsideCurrent Analyst Ratings BreakdownLatest CRVS, XERS, PFSCF, MRKR, and ACRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.008/12/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRXAcelRx Pharmaceuticals$1.77M0.00N/AN/A$2.65 per share0.00CRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/AMRKRMarker Therapeutics$6.59M1.86N/AN/A$1.73 per share0.55PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08XERSXeris Biopharma$246.03M4.83N/AN/A($0.20) per share-36.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRXAcelRx Pharmaceuticals$47.76M-$2.23N/AN/AN/AN/A-81.54%-46.02%N/ACRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%11/13/2025 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/AXERSXeris Biopharma-$54.84M-$0.21N/AN/AN/A-13.01%N/A-8.00%11/14/2025 (Estimated)Latest CRVS, XERS, PFSCF, MRKR, and ACRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 million8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/7/2025Q2 2025XERSXeris Biopharma-$0.03-$0.01+$0.02-$0.01$64.58 million$67.71 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRXAcelRx PharmaceuticalsN/AN/AN/AN/AN/ACRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRXAcelRx PharmaceuticalsN/A4.044.04CRVSCorvus PharmaceuticalsN/A8.918.91MRKRMarker TherapeuticsN/A3.453.45PFSCFProMetic Life SciencesN/A0.950.71XERSXeris BiopharmaN/A1.951.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRXAcelRx Pharmaceuticals19.79%CRVSCorvus Pharmaceuticals46.64%MRKRMarker Therapeutics22.39%PFSCFProMetic Life Sciences0.10%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipACRXAcelRx Pharmaceuticals3.00%CRVSCorvus Pharmaceuticals31.30%MRKRMarker Therapeutics7.80%PFSCFProMetic Life SciencesN/AXERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRXAcelRx Pharmaceuticals1916.95 million16.44 millionOptionableCRVSCorvus Pharmaceuticals3074.51 million51.19 millionOptionableMRKRMarker Therapeutics6012.94 million11.93 millionNot OptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionableXERSXeris Biopharma290161.48 million154.12 millionOptionableCRVS, XERS, PFSCF, MRKR, and ACRX HeadlinesRecent News About These CompaniesAQR Capital Management LLC Has $5.20 Million Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 15 at 3:18 AM | marketbeat.comInsider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,500 Shares of StockSeptember 14 at 5:32 PM | marketbeat.comJacobs Levy Equity Management Inc. Acquires Shares of 255,560 Xeris Biopharma Holdings, Inc. $XERSSeptember 14 at 3:26 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $7.08 Average PT from BrokeragesSeptember 14 at 2:21 AM | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Director Sells $119,660.00 in StockSeptember 13 at 6:54 AM | insidertrades.comFred Alger Management LLC Buys New Stake in Xeris Biopharma Holdings, Inc. $XERSSeptember 13 at 4:07 AM | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 12, 2025 | marketbeat.comWhat Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?September 9, 2025 | zacks.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Significant Decline in Short InterestSeptember 9, 2025 | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Down 26.7% in AugustSeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $9.78 Million Stock Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 8, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Downgraded by Wall Street Zen to BuySeptember 8, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERSSeptember 7, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Holdings Raised by Graham Capital Management L.P.September 7, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Stock Rating Lowered by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comBosun Asset Management LLC Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 6, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High - Time to Buy?September 5, 2025 | marketbeat.comXeris In Recorlev-Fuelled Growth: Why I Choose To BuySeptember 5, 2025 | seekingalpha.comPDT Partners LLC Buys New Shares in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comIeq Capital LLC Boosts Holdings in Xeris Biopharma Holdings, Inc. $XERSSeptember 5, 2025 | marketbeat.comQuarry LP Makes New $388,000 Investment in Xeris Biopharma Holdings, Inc. $XERSSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVS, XERS, PFSCF, MRKR, and ACRX Company DescriptionsAcelRx Pharmaceuticals NASDAQ:ACRXAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.Corvus Pharmaceuticals NASDAQ:CRVS$5.88 +0.05 (+0.86%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.88 0.00 (-0.02%) As of 09/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Marker Therapeutics NASDAQ:MRKR$0.95 -0.01 (-0.91%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$0.92 -0.02 (-2.63%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Xeris Biopharma NASDAQ:XERS$7.36 -0.13 (-1.74%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$7.32 -0.04 (-0.61%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
